CD19 and B-cell chronic lymphocytic leukemia: Davids et al. evaluated brexucabtagene autoleucel (Brexu-cel, KTE-X19, Kite Pharmaceuticals, Inc., Santa Monica, CA, USA), a CD19-targeted CAR T-cell therapy, in 15 heavily pretreated patients with RR CLL in the phase 1 ZUMA-8 clinical trial [177,178].